Estrella Immunopharma, Inc., a clinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company’s lead product candidate is EB103, which is in clinical trial, for the treatment of diffuse large B-cell lymphoma; EB104, which is in pre-clinical trial, to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia; and EB201, which is in pre-clinical trial, for the treatment of systemic lupus erythematosus. It has a collaborative agreement with Eureka and Imugene Limited for the development of solid tumor treatments using Imugene’s product candidate CF33-CD19t in conjunction with EB103. Estrella Immunopharma, Inc. was founded in 2006 and is headquartered in EmeryVille, California.
Metrics to compare | ESLA | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipESLAPeersSector | |
---|---|---|---|---|
P/E Ratio | −2.9x | −3.1x | −0.6x | |
PEG Ratio | −0.05 | 0.02 | 0.00 | |
Price/Book | −5.8x | 2.2x | 2.6x | |
Price / LTM Sales | - | 8.7x | 3.3x | |
Upside (Analyst Target) | - | 172.5% | 39.1% | |
Fair Value Upside | Unlock | 6.5% | 5.4% | Unlock |